肥厚型心肌病与左室肥厚性疾病的影像学鉴别进展

李烨; 黄璇; 张乔柔; 姜萌

doi:10.13201/j.issn.1001-1439.2020.08.004

肥厚型心肌病与左室肥厚性疾病的影像学鉴别进展

- 上海交通大学医学院附属仁济医院心内科(上海, 200127)
基金项目:
国家自然科学基金(No:81971570)

上海申康医院发展中心促进市级医院临床技能与临床创新能力三年行动计划项目(No:16CR3020A)

浦东新区联合攻关项目(No:PW2018D-03)

医工交叉基金资助项目(No:YG2019ZDA13)

详细信息

通讯作者: 姜萌,E-mail:jiangmeng0919@163.com

中图分类号: R542.2

收稿日期: 2019-09-07

修回日期: 2020-02-03

Progress on differentiation hypertrophic cardiomyopathy from other causes of left ventricular hypertrophy

- Department of Cardiology, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China

More Information

Corresponding author: JIANG Meng, E-mail: jiangmeng0919@163.com

Received Date: 07 September 2019

Revised Date: 03 February 2020

摘要

摘要: 肥厚型心肌病(HCM)是最常见的遗传性心肌病,以心室壁过度增厚、晕厥、早发猝死为主要表现。左室肥厚是HCM的病变特征,然而现有诊断标准不能将其与心脏负荷过重引起的左室肥厚性疾病准确区分,如运动员心脏、高血压性心脏病(HHD)、心肌淀粉样变性(CA)等。本文主要对HCM与左室肥厚相关疾病的影像学鉴别进展作一综述。
- 肥厚型心肌病 /
- 运动员心脏 /
- 高血压性心脏病 /
- 心肌淀粉样变性
Abstract: Hypertrophic cardiomyopathy(HCM) is the most common genetic cardiomyopathy and is a disease characterized by left ventricle wall thickness, syncope and early sudden death. Excessive left ventricle wall thickness is the pathological feature of HCM. However, differentiating HCM from other causes of left ventricular hypertrophy, such as athlete's heart, hypertensive heart disease(HHD), cardiac amyloidosis(CA) encounters diagnostic challenges. This article reviews the research progress of radiology in this respect, providing radiological support for clinical differential diagnosis.
- hypertrophic cardiomyopathy /
- athlete's heart /
- hypertensive heart disease /
- cardiac amyloidosis

HTML全文

参考文献(39)

[1]	Semsarian C,Ingles J,Maron MS,et al.New perspectives on the prevalence of hypertrophic cardiomyopathy[J].J Am Coll Cardiol,2015,65(12):1249-1254.
[2]	Sheikh N,Papadakis M,Schnell F,et al.Clinical profile of athletes with hypertrophic cardiomyopathy[J].Circ Cardiovasc Imaging,2015,8(7):e003454.
[3]	Luijkx T,Cramer MJ,Buckens CF,et al.Unravelling the grey zone:cardiac MRI volume to wall mass ratio to differentiate hypertrophic cardiomyopathy and the athlete's heart[J].Br J Sports Med,2015,49(21):1404-1409.
[4]	Galderisi M,Cardim N,D'Andrea A,et al.The multi-modality cardiac imaging approach to the Athlete's heart:an expert consensus of the European Association of Cardiovascular Imaging[J].Eur Heart J Cardiovasc Imaging,2015,16(4):353-353.
[5]	Finocchiaro G,Dhutia H,D'silva A,et al.Role of Doppler diastolic parameters in differentiating physiological left ventricular hypertrophy from hypertrophic cardiomyopathy[J].J Am Soc Echocardiogr,2018,31(5):606-613.e1.
[6]	Ternacle J,Bremont C,d'Humieres T,et al.Left ventricular dyssynchrony and 2D and 3D global longitudinal strain for differentiating physiological and pathological left ventricular hypertrophy[J].Arch Cardiovasc Dis,2017,110(6-7):403-412.
[7]	van de Schoor FR,Aengevaeren VL,Hopman MT,et al.Myocardial fibrosis in athletes [J].Mayo Clin Proc,2016,91(11):1617-1631.
[8]	Swoboda PP,Mcdiarmid AK,Erhayiem B,et al.Assessing myocardial extracellular volume by T1 mapping to distinguish hypertrophic cardiomyopathy from athlete's heart[J].J Am Coll Cardiol,2016,67(18):2189-2190.
[9]	Lazzeroni D,rimoldi O,Camici PG.From left ventricular hypertrophy to dysfunction and failure[J].Circ J,2016,80(3):555-564.
[10]	Gould KL,Johnson NP,Bateman TM,et al.Anatomic versus physiologic assessment of coronary artery disease.Role of coronary flow reserve,fractional flow reserve,and positron emission tomography imaging in revascularization decision-making[J].J Am Coll Cardiol,2013,62(18):1639-1653.
[11]	Radvan J,choudhury L,Sheridan DJ,et al.Comparison of coronary vasodilator reserve in elite rowing athletes versus hypertrophic cardiomyopathy[J].Am J Cardiol,1997,80(12):1621-1623.
[12]	Toraa M,Pouillard F,Merlet P,et al.Cardiac hypertrophy and coronary reserve in endurance athletes[J].Can J Appl Physiol,1999,24(1):87-95.
[13]	Camici P,Chiriatti G,Lorenzoni R,et al.Coronary vasodilation is impaired in both hypertrophied and nonhypertrophied myocardium of patients with hypertrophic cardiomyopathy:a study with nitrogen-13 ammonia and positron emission tomography[J].J Am Coll Cardiol,1991,17(4):879-886.
[14]	Cecchi F,Olivotto I,Gistri R,et al.Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy[J].N Engl J Med,2003,349(11):1027-1035.
[15]	Olivotto I,Girolami F,Sciagra R,et al.Microvascular function is selectively impaired in patients with hypertrophic cardiomyopathy and sarcomere myofilament gene mutations[J].J Am Coll Cardiol,2011,58(8):839-848.
[16]	Neglia D,Fommei E,Varela-carver A,et al.Perindopril and indapamide reverse coronary microvascular remodelling and improve flow in arterial hypertension[J].J Hypertens,2011,29(2):364-372.
[17]	Rimoldi O,Rosen SD,Camici PG.The blunting of coronary flow reserve in hypertension with left ventricular hypertrophy is transmural and correlates with systolic blood pressure[J].J Hypertens,2014,32(12):2465-2471,discussion 2471.
[18]	Dorbala S,Vangala D,Bruyere J Jr,et al.Coronary microvascular dysfunction is related to abnormalities in myocardial structure and function in cardiac amyloidosis[J].JACC Heart Fail,2014,2(4):358-367.
[19]	Knott KD,Augusto JB,Nordin S,et al.Quantitative myocardial perfusion in Fabry disease[J].Circ Cardiovasc Imaging,2019,12(7):e008872.
[20]	Elliott PM,Kindler H,Shah JS,et al.Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A[J].Heart,2006,92(3):357-360.
[21]	Tomberli B,Cecchi F,Sciagra R,et al.Coronary microvascular dysfunction is an early feature of cardiac involvement in patients with Anderson-Fabry disease[J].Eur J Heart Fail,2013,15(12):1363-1373.
[22]	Rodrigues JC,Rohan S,Dastidar AG,et al.Hypertensive heart disease versus hypertrophic cardiomyopathy:multi-parametric cardiovascular magnetic resonance discriminators when end-diastolic wall thickness≥ 15 mm[J].Eur Radiol,2017,27(3):1125-1135.
[23]	Teo EP,Teoh JG,Hung J.Mitral valve and papillary muscle abnormalities in hypertrophic obstructive cardiomyopathy[J].Curr Opin Cardiol,2015,30(5):475-482.
[24]	Jiang M,Wang Z,Su X,et al.The Significance of Interstitial Fibrosis on Left Ventricular Function in Hypertensive versus Hypertrophic Cardiomyopathy[J].Sci Rep,2018,8(1):9995.
[25]	Hayashi S,Yamada H,Nishio S,et al.Tricuspid annular motion velocity as a differentiation index of hypertrophic cardiomyopathy from hypertensive heart disease[J].J Cardiol,2015,65(6):519-525.
[26]	Okada K,Yamada S,Iwano H,et al.Myocardial shortening in 3 orthogonal directions and its transmural variation in patients with nonobstructive hypertrophic cardiomyopathy[J].Circ J,2015,79(11):2471-2479.
[27]	Afonso L,Briasoulis A,Mahajan N,et al.Comparison of right ventricular contractile abnormalities in hypertrophic cardiomyopathy versus hypertensive heart disease using two dimensional strain imaging:a cross-sectional study[J].Int J Cardiovasc Imaging,2015,31(8):1503-1509.
[28]	Hoit BD.Left atrial size and function:role in prognosis[J].J Am Coll Cardiol,2014,63(6):493-505.
[29]	Hinojar R,Varma N,Child N,et al.T1 mapping in discrimination of hypertrophic phenotypes:hypertensive heart disease and hypertrophic cardiomyopathy:findings from the International T1 Multicenter Cardiovascular Magnetic Resonance Study[J].Circ Cardiovasc Imaging,2015,8(12):e003285.
[30]	Schofield R,Ganeshan B,Fontana M,et al.Texture analysis of cardiovascular magnetic resonance cine images differentiates aetiologies of left ventricular hypertrophy[J].Clin Radiol,2019,74(2):140-149.
[31]	Neisius U,El-rewaidy H,Nakamori S,et al.Radiomic analysis of myocardial native T1 imaging discriminates between hypertensive heart disease and hypertrophic cardiomyopathy[J].JACC Cardiovasc Imaging,2019,12(10):1946-1954.
[32]	Siddiqi OK,Ruberg FL.Cardiac amyloidosis:an update on pathophysiology,diagnosis,and treatment[J].Trends Cardiovasc Med,2018,28(1):10-21.
[33]	Pagourelias ED,Duchenne J,Mirea O,et al.The relation of ejection fraction and global longitudinal strain in amyloidosis:implications for differential diagnosis[J].JACC Cardiovasc Imaging,2016,9(11):1358-1359.
[34]	Everett R,Stirrat C,Semple S,et al.Assessment of myocardial fibrosis with T1 mapping MRI[J].Clin Radiol,2016,71(8):768-778.
[35]	Baggiano A,Boldrini M,Martinez-naharro A,et al.Noncontrast magnetic resonance for the diagnosis of cardiac amyloidosis[J].JACC Cardiovasc Imaging,2020,13(1):69-80.
[36]	Cappelli F,Gallini C,Di Mario C,et al.Accuracy of 99mTc-Hydroxymethylene diphosphonate scintigraphy for diagnosis of transthyretin cardiac amyloidosis[J].J Nucl Cardiol,2019,26(2):497-504.
[37]	Lee SP,Suh H-Y,Park S,et al.Pittsburgh B Compound Positron Emission Tomography in Patients With AL Cardiac Amyloidosis[J].J Am Coll Cardiol,2020,75(4):380-390.
[38]	Nordin S,Kozor R,Bulluck H,et al.Cardiac Fabry disease with late gadolinium enhancement is a chronic inflammatory cardiomyopathy[J].J Am Coll Cardiol,2016,68(15):1707-1708.
[39]	Karur GR,Robison S,Iwanochko RM,et al.Use of myocardial T1 mapping at 3.0 T to differentiate Anderson-Fabry disease from hypertrophic cardiomyopathy[J].Radiology,2018,288(2):398-406.